Treatment & Pathogenesis of Skin Cancer, Disorders of Cornification & Pso

治疗

• 批准号: 6100537
• 负责人: JOHN J DIGIOVANNA
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6100537
• 关键词: 13 cis retinoate; adolescence (12-20); bone density; bone imaging /visualization /scanning; bone metabolism; cancer prevention; chemoprevention; child (0-11); clinical research; clinical trial phase I; dosage; drug adverse effect; human subject; human therapy evaluation; osteoporosis; phospholipase inhibitor; psoriasis; retinoids; skin disorder chemotherapy; skin neoplasms; topical drug application; vitamin therapy; xeroderma pigmentosum

A study of the efficacy and toxicity of isotretinoin as a chemopreventive agent is being continued in a series of eight patients with xeroderma pigmentosum. Initial results identified an improvement of great magnitude in the rate of new skin cancer formation while on high dose therapy. However, high dose therapy was associated with significant toxicity. Patients continut to be evaluated at intermediate doses in an effort to achieve adequate chemoprevention with minimum toxicity and further define the parameters of isotretinoin chemoprevention. One patient had similar benefit on both low and high dose treatment. Four patients had less improvement on low as compared to high dose treatment. This suggests a dose response. One patient had no benefit from high dose isotretinoin and has been started on a study of oral acitretin, an aromatic retinoid. Osteoporosis has been observed in chronic hypervitaminosis A. We had previously identified decreased bone mineral density in a group of etretinate treated patients. We have continued to study retinoid osteoporosis by evaluating bone mineral densities using DEXA scanning, and continue to valuate bone mineral density and parameters of bone turnover. A phase I/II, double-blind study of topical antiflammin, a phospholipase-A2 inhibitor, for the treatment of psoriasis, is in progress. Fourteen patients have been enrolled at three dose levels and enrollment is continuing. Previous projects evaluating the long-term efficacy and toxicity of the retinoids, isotretinoin and etretinate, in the treatment of the skin cancer, disorders of cornification, and psoriasis have been terminated.

异维A酸口服液的疗效和毒性研究 一种化学预防剂正在连续八次 着色性干皮病患者。初步结果表明， 新皮肤癌发病率大幅下降 在高剂量治疗时形成。然而，高剂量治疗 与严重的毒性有关。患者继续 在中等剂量下进行评价，以达到足够的 最小毒性的化学预防，并进一步定义 异维A酸化学预防的参数。1例患者有类似 对低剂量和高剂量治疗都有好处。四名患者的 与高剂量治疗相比，低剂量治疗的改善。这 表明存在剂量反应一名患者没有从高剂量中获益。 剂量异维甲酸，并已开始口服阿维A的研究， 一种芳香类维生素A骨质疏松症已被观察到在慢性 维生素A过多症我们之前发现骨骼减少 一组阿维A酯治疗患者的矿物质密度。我们有 通过评估骨矿物质继续研究类维生素A骨质疏松症 密度使用DEXA扫描，并继续评估骨 骨密度和骨转换参数。一期/二期， 局部抗炎蛋白（一种磷脂酶A2）的双盲研究 治疗牛皮癣的方法有哪些？十四 患者已入组三个剂量水平，入组人数为 继续。以前的项目评估长期疗效和 类维生素A、异维A酸和依维A酯在治疗中的毒性 皮肤癌、角化障碍和牛皮癣的发病率 被终结了